Company intelligence / Profile preview
Bright Peak Therapeutics
Basel, Basel-Stadt, Switzerlandbrightpeaktx.com ↗
- Ownership
- Private
- Employees
- ~40
- Development stage
- Phase 1
01
Overview
The company’s lead asset, BPT567—a first-in-class bifunctional PD1–IL18 immunoconjugate—entered Phase 1/2a trials in October 2024 for patients with advanced solid tumors. Preclinical data showed potent anti-tumor activity, including potential efficacy in settings where conventional PD‑1 inhibitors have failed. Additional pipeline programs are at preclinical stages targeting cancer and autoimmune diseases
- Therapeutic areas
- OncologyImmunology
- Modalities
- Immune-stimulating antibody conjugates (ISACs)Recombinant polypeptides/proteinsCytokinesImmunoconjugates
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Request access →03
Partnerships
Ajinomoto Co., Inc.: Research collaboration and license agreement to create novel immunocytokinesLivzon Pharmaceutical Group Co., Ltd.: Agreement to use LZM009 anti-PD–1 mAb for development of novel immunocytokinesVersant Ventures as founding investor and ongoing partner/supporter.
Beyond the preview
Go deeper on Bright Peak Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bright Peak Therapeutics.